Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QA102 Phase 1 study in healthy volunteers
NCT04894071Phase 1Completed
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in age-related macular degeneration (AMD) comparing QA102 with Placebo (2 arms). Primary endpoint: Incidence and severity of Adverse Events. Started May 2021; status: completed.
02
Drugs
QA102
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT04894071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894071.